Solbec Announces Grant Of Australian Patent
SOLBEC ANNOUNCES GRANT OF AUSTRALIAN PATENT
· Solbec advises the granting of Australian patent, number 779512, entitled “Medicinal compositions and their method of preparation”.
Perth, Australia. 14 June 2005. Solbec Pharmaceuticals (ASX: SBP) advises that the Australian patent, number 779512, entitled “Medicinal compositions and their method of preparation” has been granted. This provides additional protection to the Company’s lead compound Coramsine™. The term of the patent runs until April 2020.
The “Medicinal compositions” patent covers aspects of the manufacturing, purification process and formulation of the active pharmaceutical ingredients of Coramsine™. It is the second Coramsine™ related patent application to be granted. International cases of the application are ongoing.
Coramsine™ is now covered by seven families of patents /
patent applications that are expected to provide protection
until 2023. They extend to clinical application, extraction
and purification, the cell receptor involved in Coramsine™
selectivity, Coramsine’s™ effect on Interleukin-6
production, and Coramsine™ combination therapy.
Solbec Pharmaceuticals Ltd identifies naturally-occurring compounds with potential in the development of better therapies for debilitating conditions and life-threatening diseases. The company is currently progressing its key project, Coramsine™, through Phase I/IIA clinical trials for the treatment of advanced solid tumours, and as a topical treatment for psoriasis. Solbec's two proprietary ingredients in Coramsine™ were isolated from the fruit of a plant known as the Devil’s Apple (Solanum linnaeanum). They show activity against some cancers and cause potentially therapeutic changes to the immune system. In addition to human health, Coramsine™ has potential application in the areas of animal health and diagnostics. Solbec’s business strategy is to partner or out-license Coramsine™ for the final stages of pre-commercial development and marketing.